| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IGLV6-57 |
| Uniprot No | P01721 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-148aa |
| 氨基酸序列 | MAWAPLLLTLLAHCTGSWANFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGRAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNHTVLQTHGEVRQKLPRASLPGPVSACLHRRG |
| 分子量 | 42.5 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人IGLV6-57蛋白的参考文献示例(注：以下内容为模拟生成，实际文献需通过学术数据库检索确认)：
---
1. **文献名称**：*Structural characterization of recombinant human IGLV6-57 protein in antibody diversity*
**作者**：Smith J, et al.
**摘要**：研究通过大肠杆菌系统表达重组人IGLV6-57蛋白，利用X射线晶体学解析其三维结构，揭示其在免疫球蛋白可变区多样性中的构象变化机制。
2. **文献名称**：*Expression and functional analysis of IGLV6-57 in B-cell malignancies*
**作者**：Wang L, et al.
**摘要**：探讨重组人IGLV6-57蛋白在慢性淋巴细胞白血病(CLL)中的异常表达，并通过体外实验证明其可能作为B细胞恶性肿瘤的生物标志物。
3. **文献名称**：*High-yield production of recombinant IGLV6-57 using mammalian cell systems*
**作者**：Garcia R, et al.
**摘要**：优化HEK293细胞表达体系，实现重组人IGLV6-57的高效分泌表达和纯化，为后续抗体工程设计提供可扩展的生产方法。
4. **文献名称**：*IGLV6-57 interactions with antigens: Insights from surface plasmon resonance*
**作者**：Chen H, et al.
**摘要**：通过表面等离子体共振(SPR)技术，分析重组人IGLV6-57蛋白与特异性抗原的结合动力学，验证其在抗体-抗原识别中的潜在功能位点。
---
建议通过**PubMed**或**Google Scholar**以关键词“recombinant IGLV6-57”或“IGLV6-57 protein”检索真实文献。如需具体文献协助，可进一步说明需求。
Recombinant human IGLV6-57 protein is a genetically engineered variant of the immunoglobulin lambda variable 6-57 (IGLV6-57) chain, a component of the human immune system’s antibody repertoire. Immunoglobulin lambda (Igλ) light chains, paired with heavy chains, form antigen-binding regions of antibodies, enabling adaptive immunity. The IGLV6-57 gene, part of the immunoglobulin lambda variable (IGLV) gene cluster on chromosome 22q11.2. encodes the variable domain of the lambda light chain. This domain contributes to antibody diversity through combinatorial rearrangement during B-cell development.
The recombinant version is typically produced in expression systems like *E. coli* or mammalian cells to study its structure, function, and potential therapeutic applications. Its production enables research into B-cell receptor signaling, antibody-antigen interactions, and immune-related pathologies. Dysregulation of lambda light chains, including IGLV6-57. has been implicated in autoimmune diseases and B-cell malignancies, making this protein relevant for biomarker discovery or targeted therapies.
In biotechnological contexts, recombinant IGLV6-57 may serve as a tool for antibody engineering, epitope mapping, or standardizing diagnostic assays. Analytical methods such as X-ray crystallography or surface plasmon resonance (SPR) often utilize this protein to elucidate binding mechanisms. Rigorous quality controls ensure proper folding and post-translational modifications, critical for functional studies. Overall, it bridges fundamental immunology research with translational applications in disease diagnosis and treatment.
×
